Age is a prognostic factor even among patients with multiple myeloma younger than 66 years treated with high-dose melphalan: the IFM experience on 2316 patients

作者：Chretien Marie Lorraine; Hebraud Benjamin; Cances Lauwers Valerie; Hulin Cyrille; Marit Gerald; Leleu Xavier; Karlin Lionel; Roussel Murielle; Stoppa Anne Marie; Guilhot Francois; Lamy Thierry; Garderet Laurent; Pegourie Brigitte; Dib Mamoun; Sebban Catherine; Lenain Pascal; Brechignac Sabine; Royer Bruno; Wetterwald Marc; Legros Laurence; Orsini Piocelle Frederique; Voillat Laurent; Delbrel Xavier; Caillot Denis; Macro Margaret; Facon Thierry; Attal Michel

来源：Haematologica-The Hematology Journal, 2014, 99(7): 1236-1238.

DOI：10.3324/haematol.2013.098608

Age is a strong prognostic factor in multiple myeloma. The overall survival is shorter in patients older than 66 years, and even shorter in those older than 75 years. Whether age is also a prognostic parameter in patients younger than 66 years treated homogeneously with intensive approaches is unknown. To address this issue, we retrospectively analyzed a series of 2316 patients treated homogeneously with 3-4 cycles of induction chemotherapy followed by a high-dose melphalan course, without any consolidation or maintenance. We show that patients older than 60 years have a statistically significant shorter overall survival. The analysis of prognostic parameters did not show a higher incidence of high-risk cytogenetics, but a higher incidence of International Staging System (ISS) stages 2 and 3, mainly due to higher beta 2-microglobulin levels. This study is the first to demonstrate the impact of age in the outcome of %26apos;young%26apos; patients with multiple myeloma, and suggests that this parameter should be included in the stratification factors for future prospective clinical trials.

• 出版日期2014-7-1